significant cardiac blood flow obstruction (aortic jet velocity of <2.0 m per s) 3 . The prevalence of aortic sclerosis increases sharply with age. In developed countries, it is estimated to be 25% in those >65 years old and almost 50% in those aged >85 years [9] [10] [11] . According to a recent meta-analysis, the rate of progression to AS in individuals with aortic sclerosis is 1.8-1.9% of patients per year 11 . Therefore, the prevalence of calcific AS is much lower than that of aortic sclerosis, and has been estimated to be 0.4% in the general population and 1.7% in the population >65 years of age 12 in developed countries. There is a marked increase in the prevalence of calcific AS in those >65 years, as reported by several population-based studies in the United States and Europe 9, [13] [14] [15] (FIG. 1) . For individuals aged ≥75 years, a pooled analysis of available epidemiological data in developed countries produced an estimated severe AS prevalence of 3.4% (95% confidence interval of 1.1-5.7%), with 75% of those with severe AS presenting with symptoms 16 . The incidence of calcific AS has been assessed in a longitudinal Norwegian study and was estimated to be 4.9 per 1,000 people per year in a population that had a mean age of 60 years at inclusion 13 . The geographical distribution of calcific AS is heterogeneous and shows a clustering effect, which is probably the consequence of genetic factors 17 . Although mitral valve regurgitation has a higher prevalence than AS in population-based studies, AS has a more important clinical effect 18 . In the Euro Heart Survey, AS was more prevalent than mitral valve regurgitation in patients who were referred for in-hospital care and cardiac surgery 18 . Furthermore, calcific AS accounted for 34% of all native (that is, non-prosthetic) valve diseases, whereas mitral regurgitation accounted for 25%; and calcific AS accounted for 47% of patients operated for valvular disease, whereas mitral regurgitation accounted for 14% (REF. 18 ).
The burden of calcific AS in the community is expected to increase over the next decades owing to population ageing and the lack of a prevention strategy to reduce disease progression. Estimates based on current prevalence rates and demographic forecasts predict that the number of patients with calcific AS who are >70 or >75 years of age will increase twofold to threefold over the next 50 years in developed countries 15, 16, 19 .
The epidemiology of AS in developing countries and resource-poor settings differs in some respects to that seen in developed countries, partly because of the higher rates of rheumatic fever and rheumatic heart disease in poorer communities. Rheumatic heart disease is a chronic condition resulting from acute rheumatic fever, which in turn is caused by an untreated throat infection with group A Streptococcus. Both rheumatic fever and rheumatic heart disease may cause damage to the heart valves and can result in stenosis and regurgitation, particularly of the mitral and aortic valves. Valvular remodelling markedly differs between rheumatic heart disease and calcific AS. Fusion of aortic leaflets at commissures is one hallmark and distinctive feature of rheumatic heart disease; a disease that rarely affects the aortic valve alone (less than 10% of all cases of valvular heart disease in countries in which rheumatic fever remains endemic) and most often involves the mitral valve. When the aortic valve is affected, the dysfunction is often mixed: aortic stenosis combined with some degree of aortic regurgitation 20, 21 . The proportion of AS caused by calcific AS is expected to increase in industrially developing countries owing to the decreasing incidence of rheumatic fever. In addition, the overall burden of calcific AS is expected to increase owing to the increase in life expectancy in these regions.
Mechanisms/pathophysiology
For a long time, calcific aortic valve disease was thought to be a 'degenerative' process caused by time-dependent wear and tear of the leaflets and passive calcium deposition. There are now compelling histopathological and clinical data suggesting that calcific valve disease is, in fact, an active and multifaceted condition involving lipoprotein deposition, chronic inflammation, osteoblastic transition of valve interstitial cells and active leaflet calcification 22, 23 .
Aortic valve anatomy and remodelling
The aortic valve is typically composed of three leaflets that are named according to their location with respect to the coronary artery; specifically, the left coronary, right coronary and non-coronary leaflets (FIG. 2) . Each leaflet has a trilaminar structure that determines the biomechanical properties of the aortic valve 24 . The outermost layers of the leaflet are formed by the fibrosa and ventricularis, which face the aorta and the left ventricular outflow tract, respectively. The spongiosa, which has a high proteoglycan content, is located between the fibrosa and ventricularis (FIG. 3) . The fibrosa is rich in circumferentially oriented collagen type I and III fibres 25 , whereas in the ventricularis, radially oriented elastic fibres predominate. The ventricularis composition provides compliance (that is, the ability to expand under pressure) and allows the apposition of free edge regions of leaflets, thus preventing the backwards flow of blood into the left ventricle during diastole. The cellular population of these aortic valve layers includes valve interstitial cells (VICs), smooth muscle cells (SMCs; <5% of the population) and endothelial cells. The endothelial cells cover the aortic and ventricular surface and therefore provide an interface between the blood and the aortic valve 26 . VICs are the predominant cells in the aortic valve, whereas SMCs reside at the base of the ventricularis 27 . 1 Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri, USA.
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Inspection of surgically explanted valves with calcific AS reveals two features, fibrosis and calcification (FIG. 3) , which substantially alter the biomechanical properties of the aortic valve leaflets. A small proportion (10-15%) of calcific AS valves show advanced osteogenic metaplasia with the presence of osteoblast-like cells, chondrocytes and bone marrow 28 . Calcified valves often contain dense inflammatory infiltrates, which mostly consist of macrophages 29, 30 . Mineralization starts in the fibrosa layer and is often localized in the vicinity of lipid deposits. Together, these observations suggest that the fibrocalcific process in the aortic valve is a response to injury, which might be triggered by lipid-derived species and inflammation 31 (FIG. 4) .
In addition, excess production and disorganization of collagen fibres is an important feature of calcific AS. Fibrosis increases the stiffness of the aortic valve and might play a considerable part in promoting mineralization. To this effect, the collagen produced by VICs functions as a scaffold on which the nucleation of calcium and phosphorus can start 32 . Serum-induced mineralization of collagen is increased in vitro by a popu lation of VICs that have a pro-calcifying phenotype with elevated alkaline phosphatase (ALP) expression 33, 34 . Furthermore, the increased production of several components of the extracellular matrix, including periostin, tenascin (also known as tenascin C) and proteoglycans contributes to the remodelling of the aortic valve during AS 35, 36 . The exact role of non-collagenous proteins in the pathophysiology of AS is still mostly unknown, but growing evidence indicates that complex interactions between extracellular matrix proteins and cells provide crucial signals during normal reparative and pathological processes in the aortic valve 37 .
Lipids
Lipid infiltration and oxidation. Increasing evidence suggests that infiltration of the aortic valve by lipoproteins has a central role in promoting inflammation, which precedes the pathological mineralization that is characteristic of calcific AS 38 . Therefore, the retention of lipids promotes a chronic low-grade inflammatory • Severe leaflet calcification or congenital stenosis with a severely reduced leaflet opening • Severe AS with low gradient ‡
• Small left ventricular cavity with pronounced concentric remodelling, restrictive diastolic filling, and low-flow but normal LVEF • Symptoms include heart failure, angina, syncope or pre-syncope process that, in turn, might induce an osteogenic program in aortic valves. In this regard, histological studies have shown that several apolipoproteins (apos), such as apoB, apoE, apoA1 and apo(a), are present in surgically removed stenotic aortic valves 39 . Oxidative stress has also been implicated in calcific AS. For instance, immunostaining has shown that apoB colocalizes with oxidized low-density lipoproteins (Ox-LDLs) in valves from patients with calcific AS 40, 41 , and that there is an association between the level of Ox-LDL and the degree of inflammation and fibro-calcific remodelling in surgically removed AS valves 40, 42 . Oxidative stress is increased in AS valves and is at least partly related to the uncoupling of the nitric oxide synthase (NOS) pathway 43 . In addition, the expression NAD(P)H oxidase is increased in surgically explanted calcific AS valves and contributes to the production of reactive oxygen species (ROS) 44 . Therefore, the production of peroxide and superoxide anions in the vicinity of calcified areas might participate in the production of oxidatively modified lipid species with osteogenic properties 43 . Work carried out in vitro has shown that Ox-LDL and several oxidized phospholipid (Ox-PL) species promote the calcification of isolated vascular cells 45 . Circulating Ox-PLs are mostly carried in vivo by lipoprotein(a) (Lp(a)) 46 , which is an LDL-like particle in which the apoB protein is linked by a disulphide bridge to apo(a) 47 . Recent studies that used a Mendelian randomization design showed that the gene encoding apo(a) (LPA) is potentially causally related to calcific aortic valve disease [48] [49] [50] . In addition, Capoulade and colleagues showed that circulating Lp(a) and Ox-PL levels were independently associated with faster progression of calcific AS 51 . Together, these studies suggest that high circulating levels of Lp(a) might promote the accumulation of Ox-PLs in the aortic valve, which could, in turn, trigger an osteogenic response (FIG. 4) .
Lipid retention and enzymatically modified lipid species. Proteoglycans such as biglycan and decorin are overexpressed in aortic valves during calcific AS and might actively participate in lipid retention and modification [52] [53] [54] (FIG. 4) . Moreover, transforming growth factor β1 (TGFβ1), which is activated in calcific AS, has been shown to promote the elongation of glycosaminoglycan (GAG) chains 55 . In turn, GAG chain elongation increases the interaction between proteoglycans and lipoproteins 55 . The accumulation and retention of lipoproteins in the aortic valve is a crucial event as lipids might be used by different enzymes to produce bioactive lipid-derived compounds, such as lysophospholipids 56 . Lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) levels are increased in stenotic aortic valves and this increase is associated with fibro-calcific remodelling 57, 58 ( FIG. 4) . Circulating levels of Lp-PLA 2 are also positively and independently related to the progression of calcific AS 59 . Lp-PLA 2 is transported by apoB-containing lipoproteins and is enriched in small, dense LDL and Lp(a) 60 . Lp-PLA 2 transforms Ox-PLs into lysophosphatidylcholine (lysoPC), which promotes the loss of mitochondrial membrane potential and apoptosis of VICs 57, 61 . In addition, Bouchareb and colleagues 62 recently showed that ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; also known as autotaxin), a lysophospholipase D, is probably transported into the aortic valve by Lp(a) and is also secreted by VICs in response to diverse stimuli, including tumour necrosis factor (TNF; also known as TNFα) 62 . Autotaxin transforms lysoPC into lysophosphatidic acid (lysoPA). Of interest, in vitro knockdown of autotaxin prevents the mineralization of VICs induced by lysoPC, which suggests that lysoPA is probably the mediator that promotes osteogenic programming in VICs. To this effect, in a mouse model, the administration of lysoPA increased the deposition of hydroxyapatite (a form of calcium apatite) in the aortic valve and accelerated the development of calcific AS. Therefore, it is possible that autotaxin and lysoPA are key factors that explain the link between Lp(a) and AS 63 . In addition to lysophospholipids, the arachidonic acid pathway, which produces leukotrienes and prostaglandins, has been shown to play a considerable part in the mineralization of the aortic valve 64 (FIG. 4) . For instance, the expression of 5-lipoxygenase, which is required for leukotriene synthesis, is increased in aortic valves during calcific AS, and leukotriene C4 promotes the expression of bone morphogenetic protein 2 (BMP2) and BMP6 as well as the mineralization of VICs in culture 64 . A recent study showed that prostaglandin G/H synthase 2 (PTGS2; also known as cyclooxygenase 2 (COX2)) is expressed by VICs isolated from AS valves . In support of a role for COX2 in calcific AS, loss of function of Cox2 in klotho-deficient mice, which develop Nature Reviews | Disease Primers Prevalence (%) 15 , in which AS was defined as an indexed aortic valve area of ≤0.6 cm² per m².
calcification of the aortic valve amongst other features, reduced the mineralization of the aortic valve 65 . Taken together, these findings suggest that several processes promote the retention of lipids in the aortic valve and produce bioactive lipid species, which in turn promote inflammation and mineralization of aortic valve leaflets.
Inflammation
Tissue remodelling and neovascularization. Fibrocalcific remodelling and inflammation of the aortic valve are intricately linked processes with important crosstalk. Inflammatory infiltrate in mineralized aortic valves that have been removed surgically is composed of macrophages, mast cells, CD4 + T cells and CD8 + T cells 66 . Several oxidized lipid species might activate the innate immune response through Toll-like receptors (TLRs) and the nuclear factor-κB (NF-κB) pathway. TLRs are also expressed by VICs (in the case of TLR2 and TLR4) and may promote an osteogenic phenotype in isolated VICs 67, 68 . Conversely, the role of adaptive immunity in calcific AS is still mostly unknown, but studies have shown that a subset of memory T cells is activated during AS and that clonal expansion of a T cell receptor repertoire is present in surgically removed calcific AS valves 69 . These data suggest that both innate and adaptive immune responses are probably involved in the pathobiology of calcific AS.
A histopathological study carried out on 285 aortic valves from patients with calcific AS showed that the presence of dense, chronic inflammatory infiltrates was related to the remodelling score of the leaflets and to the presence of neovascularization 29 . Although the exact role of neovascularization in driving AS is still mostly unknown, it is possible that it is involved in the recruitment of inflammatory and osteoprogenitor cells (FIG. 4) . In support of this hypothesis, mice that are deficient in chondromodulin 1 (encoded by Lect1), which is an anti-angiogenic factor, have thickened and mineralized aortic valve leaflets 70 Cytokines. TNF is secreted by monocytes and macrophages, and activates TNF receptor superfamily member 1A (TNFR1). TNFR1 activation results in activation of NF-κB and its downstream targets, including IL-1β and IL-6) (REFS 75-78) (FIG. 4) . These cytokines promote the mineralization of VICs and activate an osteogenic programme, which may involve the expression of homeobox protein MSX2 . To this effect, treatment of adventitial fibroblasts with TNF increased the expression of MSX2 through the production of ROS 79 . Mice that are deficient in IL-1 receptor antagonist protein (IL-1RN; encoded by Il1rn) have higher plasma levels of TNF than wild-type mice and develop a thickening of the aortic valve 78 . However, Il1rn −/− Tnf −/− mice are protected and do not develop a thickening of the aortic valve, which suggests that TNF plays an important part in promoting the remodelling of the aortic valve. In humans, the expression of TNF ligand superfamily member 10 (TNF10; also known as TRAIL), which is a member of the TNFrelated cytokines, is increased in calcific AS valves and promotes the mineralization of VIC cultures through death receptor 4 (REF. 80 ).
IL-6, another cytokine with pleiotropic activities, has been implicated in calcific AS. IL-6 is increased in human calcified stenotic valves and is secreted in large amounts by cultured human VICs when they are treated with an osteogenic medium 81 . In addition, knockdown of IL6 substantially reduces the expression of BMP2 and the mineralization of VIC cultures 81 . Moreover, although it has not yet been investigated in VICs, IL-6 induces the expression of receptor activator of NF-κB ligand (RANKL; also known as TNFSF11) in bone cells, which activates its cognate receptor RANK (also known as TNFRSF11A) 82 . Overexpression of RANKL during calcific AS might have an important role in pathogenesis, as secreted RANKL activates VICs to produce extracellular matrix 83 (FIG. 4) . In support of this role, the administration of osteoprotegerin (OPG; also known as TNFRSF11b), which is a decoy receptor for RANKL, to low-density lipoprotein receptor knockout (Ldlr −/− ) mice decreased calcification and the expression of osteogenic genes in aortic valves 84 . Of interest, in bone, RANKL is expressed by osteoblasts and promotes the resorption of mineral by osteoclasts. Therefore, it is possible that a dysregulation of RANKL-RANK-OPG explains the link between osteoporosis and vascular and valvular calcification 66 . In this regard, several epidemiological studies have underlined an association between osteoporosis and vascular and/or valvular calcification 66, [85] [86] [87] .
Angiotensin II
Angiotensin-converting enzyme (ACE) and chymase are overexpressed in calcific AS valves and are involved in the production of angiotensin II 88, 89 (FIG. 4) . Chymase is secreted by mast cells present in calcific AS valve tissues and converts angiotensin I into angiotensin II 88 . In addition, patients with calcific AS have elevated blood plasma levels of angiotensin II, which correlates with the valvular expression of TNF and IL-6 (REF. 90 ). Angiotensin II is a potent activator of the NF-κB pathway and promotes a strong fibrotic response in isolated cells. In mice, the administration of angiotensin II promotes fibrosis of the aortic valve 91 . Moreover, in a rabbit model of hypercholesterolaemia, the administration of olmesartan, which is an angiotensin receptor blocker (ARB), prevents the thickening of the aortic valve that normally develops in these rabbits 92 . Retrospective non-randomized studies have reported that administration of ARBs, but not ACE inhibitors, is associated with less fibro-calcific remodelling of aortic valve leaflets and slower progression of valve stenosis 93, 94 . Therefore, it is possible that a substantial amount of angiotensin II is produced by chymase in the aortic valve, the effect of which is blocked downstream by ARBs but not by ACE inhibitors.
Mineralization
Osteogenic differentiation. The endothelium that covers the healthy aortic valve expresses several anti-osteogenic genes in a spatially distributed manner 95 . The endothelium that covers the aortic side of leaflets shows less expression of anti-osteogenic genes compared with the endothelium on the ventricular side. For instance, aorticside endothelium expresses lower levels of chordin and OPG, which are negative regulators of BMP2, BMP4 and RANKL. A potential explanation for this difference in expression could be shear stress. Oscillatory shear stress has been shown to modulate the expression of ~1,000 genes and ~30 microRNAs (miRNAs) in human primary cultures of aortic valve endothelial cells 96 . For instance, the expression of miRNA-187, which promotes cell growth and proliferation, was increased when these cultures were exposed to oscillatory shear. Endothelial cells covering the fibrosa (facing the aorta) are exposed to low oscillatory shear stress compared with cells facing the left ventricle. Although the functional relevance of these findings remains to be fully investigated, shear stress might at least partly explain why the fibro-calcific process predominantly occurs in the fibrosa layer. In human stenotic aortic valves, several osteogenic genes are overexpressed 72 , whereas others show altered function that can affect their role in signalling pathways. For instance, Garg and colleagues 97 showed that mutations in NOTCH1 were associated with bicuspid aortic valves, which are prone to developing calcific AS 97 . The production of reactive oxygen species (ROS) is promoted by the uncoupling of nitric oxide synthase (NOS), which increases the oxidation of lipids and further intensifies the secretion of cytokines. Enzymes transported in the aortic valve by lipoproteins (that is, LDL and Lp(a)) such as lipoprotein-associated phospholipase A2 (Lp-PLA 2 ) and ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2; also known as autotaxin (ATX)) produce lysophospholipid derivatives. ATX, which is also secreted by valve interstitial cells (VICs), transforms lysophosphatidylcholine (lysoPC) into lysophosphatidic acid (lysoPA). Several factors including lysoPA, the receptor activator of nuclear factor-κB ligand (RANKL; also known as TNFSF11) and WNT3a promote the osteogenic transition of VICs. Arachidonic acid (AA) generated by cytosolic PLA 2 promotes the production of eicosanoids (for example, prostaglandins and leukotrienes) through prostaglandin G/H synthase 2 (PTGS2; also known as COX2) and 5-lipoxygenase (5-LO) pathways, respectively. In turn, eicosanoids promote inflammation and mineralization. Chymase and angiotensin-converting enzyme (ACE) promote the production of angiotensin II, which increases the synthesis and secretion of collagen by VICs. Owing to increased production of matrix metalloproteinases (MMPs) and decreased synthesis of tissue inhibitors of metalloproteinases (TIMPs), disorganized fibrous tissue accumulates within the aortic valve. Microcalcification begins early in the disease, driven by microvesicles secreted by VICs and macrophages. In addition, overexpression of ectonucleotidases (ENPP1, 5ʹ-nucleotidase ecto (NT5E)) and alkaline phosphatase (ALP)) promotes both apoptosis and osteogenic-mediated mineralization. Bone morphogenetic protein 2 (BMP2) leads to osteogenic transdifferentiation, which is associated with the expression of bone-related transcription factors (for example, runt-related transcription factor 2 (RUNX2) and homeobox protein MSX2).
Osteoblast-like cells subsequently coordinate calcification of the aortic valve as part of a highly regulated process analogous to skeletal bone formation. Deposition of mineralized matrix is accompanied by fibrosis and neovascularization, which is abetted by vascular endothelial growth factor (VEGF). In turn, neovascularization increases the recruitment of inflammatory cells and bone marrow-derived osteoprogenitor cells. A 2A R, adenosine A 2A receptor; sPLA 2 , secreted PLA 2 ; LPAR, lysophosphatidic acid receptor; Ox-PL, oxidized phospholipid; Ox-LDL, oxidized LDL; TGFβ, transforming growth factor-β; TNF, tumour necrosis factor.
transcription factor 2 (RUNX2) in VICs 98 , suggesting that VICs are driven towards an osteogenic differentiation pathway in calcific AS. To this effect, heterozygous Notch1 +/− and Rbpj +/− mice develop mineralization of the aortic valve 99 . In addition, the NICD interferes in the nucleus with β-catenin (also known as catenin β1), a downstream effector of the WNT pathway, which is also a key driver of osteogenic differentiation 100 . A recent study in endothelial cells showed that NOTCH1 regulates the expression of more than a 1,000 genes involved in inflammation and osteogenesis by altering the epigenetic signature at enhancer regions 101 . Moreover, in human stenotic aortic valves, WNT3a, an agonist of the WNT pathway, is overexpressed 102 . The activation of a co-receptor formed by LDLR-related protein 5 and G protein-coupled Frizzled receptors, which are expressed by VICs, leads to the stabilization of β-catenin and to osteogenic differentiation 102 (FIG. 4) . In vascular cells, BMP2 promotes the expression of MSX2, a positive regulator of the WNT pathway 103 . Several factors, including inflammatory cytokines and oxidized lipid derivatives, have been shown to induce the expression of BMP2 in different cell types, including VICs 104 . Recent studies have also highlighted that the expression of several miRNAs is dysregulated in AS and this might affect the osteogenic programming of VICs. In this regard, miRNA-30b, which is decreased in mineralized aortic valves, is a negative regulator of RUNX2 (REF. 105 ). Hence, a dysfunction of Notch and WNT pathways as well as a dysregulation of miRNAs contribute to increased pro-osteogenic signals in VICs.
Mineral deposition. Osteogenic reprograming of VICs brings about a series of events that promote the deposition of a calcified matrix. The mechanism (or mechanisms) by which VICs mineralizes the extracellular matrix is still poorly defined but recent observational and experimental work suggests that cells secrete small vesicles rich in ectonucleotidases that promote the nucleation of calcium and phosphorus 106, 107 . A build-up of phosphate in calcifying vesicles, which also contain the annexin V-S100A9 complex that binds calcium, promotes the nucleation of minerals 108 . Secretion of calcifying vesicles has classically been attributed to cells that transdifferentiate into osteoblast-like cells, in which case calcification proceeds with the deposition of well-organized bone-like mineral matrix (known as hydroxyapatite of calcium) 109 . However, programmed cell death leads to the production of apoptotic bodies with similar properties to calcifying vesicles. Apoptosis of VICs is promoted by different stimuli including cytokines, ROS and altered purinergic signalling. Apoptotic bodies function as nidi for dystrophic calcification, a form of mineralization that consists of amorphous deposits of calcium and phosphorus crystals. In human aortic valves, it is likely that both osteogenic and apoptotic processes contribute to the mineralization process, and at least partly rely on ectonucleotidases 110 . In support of this involvement, several ectonucleotidases, such as ALP, ENPP1 and 5ʹ-nucleotidase (5ʹ-NT; also known as CD73), are overexpressed in human stenotic aortic valves [110] [111] [112] (FIG. 4) . These membrane-bound enzymes use nucleotides and nucleosides secreted by cells as substrates and produce phosphate-derived products that promote mineralization 112 . For instance, ENPP1 hydrolyses ATP into AMP and pyrophosphate, which is a strong inhibitor of mineralization. Conversely, ALP has a broad range of substrates, including the mineralization inhibitor pyrophosphate from which it produces phosphate with strong pro-mineralizing activity. Moreover, the overactivity of ENPP1 and 5ʹ-NT in human stenotic aortic valves depletes extracellular ATP and produces adenosine with osteogenic activity 111 . A decrease in the level of extracellular ATP also diminishes purinergic signalling through the P2Y purinoceptor 2 (P2Y2). In VICs, P2Y2 prevents the mineralization of cells by interfering with apoptosis and also by promoting the activation of carbonic anhydrase 12 (CA12) 110, 113 . CA12 in VICs is normally expressed at the cell membrane following activation of P2Y2 and promotes the acidification of the extracellular space leading to resorption of mineral deposits 113 . As such, purinergic signalling, which is under the control of ectonucleotidases, plays a central part in controlling the mineralization of the aortic valve.
In summary, studies carried out in the past several years have shown that oxidation and infiltration of the aortic valve by lipids generate several bioactive lipid species that trigger inflammation of the aortic valve. The activation of several pathways with multiple points of crosstalk disrupts the normal biology of the aortic valve and promotes fibro-calcific remodelling.
Pathophysiology of left ventricular dysfunction
The symptoms in AS are essentially due to an imbalance between the increase in left ventricular haemodynamic load caused by valvular obstruction, on the one hand, and the capacity of the left ventricle to overcome this increase in load both at rest and during exercise, on the other hand. AS results in increased left ventricular systolic pressure that leads to hypertrophy of the cardiomyocytes and interstitial fibrosis (FIG. 5) . The mechanical signal generated by increased left ventricular systolic pressure initiates a cascade of biological events, including re-expression of immature fetal genes, which leads to coordinated cardiac growth in patients with AS 114 . This increase in cardiac mass is due to the hypertrophy of existing myocytes rather than to hyperplasia, because cardiomyocytes become terminally differentiated soon after birth. The concurrent addition of sarcomeres (force-generating units) causes an increase in myocyte width, which in turn increases wall thickness and therefore contributes to normalization of left ventricular wall stress and maintenance of left ventricular ejection performance despite elevated systolic pressure. To support the increased biomechanical load, the myocyte growth must be accompanied by coordinated increases in the surrounding architecture of connective tissue as well as the capillary and nerve networks 114 . This 'reactive' interstitial fibrosis that results from the increase in collagen synthesis by myofibroblasts in response to pressure overload has a diffuse distribution within the interstitium and might be, at least partly, reversible following AVR 115 .
The pattern of the left ventricular adaptive response to pressure overload in AS is highly heterogeneous and includes concentric remodelling, concentric hypertrophy and eccentric hypertrophy (FIG. 6) . The pattern and magnitude of left ventricular hypertrophic remodelling is influenced not only by AS severity but also by several other factors, including age, sex, genetic factors, metabolic factors and the coexistence of coronary artery disease or hypertension [116] [117] [118] [119] . Among individuals with the same degree of AS, women tend to develop concentric remodelling or concentric hypertrophy most often, whereas men are more prone than women to developing eccentric hypertrophy 116 . In patients with calcific AS, left ventricular concentric remodelling or hypertrophy has been linked to worse myocardial function and increased risk of cardiac events and mortality compared with patients with normal left ventricular geometry or with left ventricular eccentric hypertrophy [120] [121] [122] . Obesity, metabolic syndrome and diabetes also predispose an individual to the development of more concentric hypertrophy in the presence of AS 117, 118 . The left ventricular hypertrophy that leads to a reduced density of coronary arteriolar vessels, and the increased left ventricular transmural pressures that lead to increased coronary vascular resistance, result in the reduction of coronary flow reserve in patients with AS 123, 124 . The reduction of coronary flow reserve limits the ability of the coronary circulation to increase flow to match myocardial oxygen demand, especially during exercise, and it is therefore a key factor in the development of myocardial ischaemia and the occurrence of symptoms. Repetitive myocardial ischaemia related to the exhaustion of coronary flow reserve leads to apoptosis of myocytes and to the development of 'replacement' myocardial fibrosis. This type of fibrosis occurs predominantly in the subendocardial and midwall layers of the left ventricle wall and is generally not reversible following relief of left ventricular pressure overload by AVR. The impairment of coronary flow reserve might also explain why patients with severe AS can present with angina symptoms despite having angiographically normal coronary arteries, and why these symptoms might regress immediately after AVR 125 . Left ventricular diastolic dysfunction occurs early in the disease course and worsens with progression of stenosis severity and myocardial fibrosis (FIG. 5) . In the more advanced stages of the disease, the increased left ventricular filling pressures lead to secondary pulmonary hypertension and dyspnoea symptoms 126, 127 . The global left ventricular systolic function, which is measured using the left ventricular ejection fraction (LVEF), and cardiac output are generally well preserved even in the presence of severe AS, because the increase in left ventricular wall thickness allows wall stress to remain relatively normal. Reduced LVEF or cardiac output occurs only in end-stage disease and is usually preceded by clinical symptoms. However, a large proportion of patients with preserved LVEF have subtle left ventricular systolic dysfunction that is characterized by impaired left ventricular longitudinal function with relatively well preserved radial and circumferential function
. The left ventricular myocardial wall is composed of three layers from the inside to the outside of the left ventricle: the subendocardial layer that surrounds the left ventricular cavity, the mid-wall layer and the subepicardial layer. In pressure overload cardiomyopathies, there is an early and selective alteration of the shortening of myocardial fibres within the subendocardial layer in which ischaemia and fibrosis are generally more pronounced [128] [129] [130] (FIG. 5) . The fibres in this layer are oriented longitudinally (compared with circumferentially in the mid-wall layer), which explains the selective alteration of the left ventricular longitudinal function in these patients. Hence, a considerable proportion of patients with AS may have subclinical left ventricular systolic dysfunction despite preserved LVEF and the absence of symptoms.
Diagnosis, screening and prevention

Risk factors and prevention
Although some clinical and genetic risk factors have been associated with the onset and progression of calcific AS, no strategy has so far been proved to be efficient for primary or secondary prevention of this disease. Calcific AS shares several risk factors with coronary artery disease but it also presents some important distinctive features.
Clinical risk factors.
Congenital leaflet abnormality and older age are both powerful risk factors for developing calcific AS. For instance, the lifetime risk of AVR is approximately 50% in individuals with a bicuspid valve. Bicuspid aortic valves have two functional leaflets often of unequal size. This abnormality results from incomplete separation of commissures during embryonic development 8 . Although leaflet orientation varies among patients, the most common form consists of a fusion of the right and left coronary leaflets (in ~60% of patients), followed by fusion between the right and the non-coronary leaflets (in ~35% of patients), and fusion between left and non-coronary cusp (in ~5% of patients) 131 (FIG. 2) . A bicuspid aortic valve is associated with an increased risk of aortopathy, in which genetic, haemodynamic and mechanical factors might participate in the mineralization of the aortic valve 132 . In individuals with a bicuspid valve and in those with a tricuspid valve, age is a powerful risk factor for AS 9, 133 . The other clinical risk factors associated with AS are similar to those associated with atherosclerosis and include male sex, smoking, hypertension, hypercholesterolaemia, obesity, metabolic syndrome, diabetes and elevated Lp(a) 9, 48, [134] [135] [136] . In patients with AS, the rate of stenosis progression over time varies substantially from one patient to another. The clinical factors associated with faster stenosis progression include older age, severity of the stenosis and the degree of aortic valve calcification at diagnosis, smoking, hypertension, obesity, metabolic syndrome, secondary hyperparathyroidism, renal failure, elevated circulating levels of Lp(a) and increased activity of Lp-PLA 2 (REFS 51,59,94,137-142). In particular, the presence of elevated plasma Lp(a) (>50 mg per dl; the upper normal limit is 30 mg per dl) is associated with a twofold faster stenosis progression 51 . In addition, hypertension, and particularly systolic hypertension, is highly prevalent in these patients, affecting 30-70% of those with AS 94, 143, 144 . Recent studies suggest that hypertension accelerates the progression of AS, potentially owing to increased mechanical stress on the valve leaflets and activation of the renin-angiotensin system (as discussed above) 94 . Moreover, hypertension further increases the left ventricular afterload (BOX 1) that is already elevated in patients with AS and contributes to the risk of developing symptoms and adverse cardiac events 94, 144 .
Genetic risk factors.
Several studies suggest that a genetic component is involved in promoting calcific AS associated with bicuspid or tricuspid aortic valves 6, 17, 48, 145 . However, despite the evidence of a strong inheritance pattern for some cases of bicuspid aortic valve with an incomplete penetrance, the genetic architecture of calcific AS is still poorly understood 145 . So far, variants of NOTCH1 and GATA-binding protein 5 (GATA5) have been associated with bicuspid aortic valves in humans 97, 146, 147 . NOTCH1 mutations explain approximately 4% of sporadic cases of AS that occur in the context of a bicuspid aortic valve 148, 149 . As discussed above, some mutations in NOTCH1 that affect its function might promote aortic valve mineralization. Therefore, it is possible that gene variants that predispose individuals to developing a bicuspid aortic valve also promote valve mineralization later in life, thus further exacerbating the risk of developing calcific AS. A recent genome-wide association study found that variants located in RUNX2 and calcium channel voltage-dependent L-type alpha 1C subunit (CACNA1C), which encode an osteogenic transcription factor and a voltage-dependent calcium channel subunit, respectively, were associated with calcific AS and were found to upregulate their respective mRNA levels 150 . Also, studies using a candidate gene approach have linked several gene variants with calcific AS. Although variants of vitamin D receptor (VDR), APOE, APOB, IL10, NOTCH1 and ENPP1 have been found to be significantly associated with AS, these studies suffer from small sample size and require replication in larger series 6 . A large study using a Mendelian randomization design identified the single-nucleotide polymorphism (SNP) rs10455872 in the LPA gene as the only genomewide significant SNP associated with the presence of aortic valve calcification and clinical calcific AS 48 . Subsequent studies have validated these findings and have also reported an association between elevated Lp(a) plasma levels and the prevalence of calcific AS, and the need for AVR in the general population [49] [50] [51] . The presence of the rs10455872 allele is associated with a 1.5-2.0-fold increase in the risk of incident calcific AS [48] [49] [50] . When considered in light of the clinical and basic research findings on Lp(a) discussed above, lowering of Lp(a) seems to be a promising novel target for the treatment of this disease, particularly to prevent disease progression. However, further studies are needed to evaluate the role of Lp(a) in AS in more detail.
A second study using a Mendelian randomization design reported a strong association between genetic predisposition to elevated LDL cholesterol, as measured by weighted genetic risk scores, and the presence of aortic valve calcification and incident cases of calcific AS 151 . However, three randomized clinical trials failed to show any significant benefit of lowering LDL using statins on the progression of AS [152] [153] [154] . Therefore, it is possible that elevated LDL cholesterol promotes the initiation of calcific aortic valve disease but has minimal or no effect on AS progression. Moreover, the protective effect of statin therapy in AS might be counterbalanced by its off-target effects, including pro-osteogenic properties, worsening of insulin resistance and increased Lp(a) levels 51, 141 . Whether other lipid-lowering strategies (for instance, proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors) would prevent or slow AS progression is unknown and this question needs to be addressed. In summary, no pharmacotherapy has proved to be effective in reducing the progression of AS.
Diagnosis
Diagnosis of AS is generally established using an echocardiographic examination, which provides a wealth of information regarding heart valve anatomy and blood flow parameters 155 (FIG. 7) . The same techniques can be used for the diagnosis of calcific AS and rheumatic AS. In the vast majority of patients, referral to echocardio graphy is motivated by the auscultation of a systolic murmur and/or the development of symptoms including dyspnoea, angina, syncope and dizziness. In some cases, AS is first recognized on echocardiography requested for other indications. Although most patients are diagnosed long before the onset of symptoms and are followed prospectively on a regular basis until AVR is indicated, a small proportion (5-10%) of patients are not diagnosed with AS until late in the disease course when they present with symptoms of heart failure 156 . The identification of the presence and stage of AS includes the assessment of the aortic valve • Carotid upstroke: the pulse pressure of the carotid artery that can be assessed at the level of the neck is characterized by a smooth, fairly rapid upstroke and a smooth, more gradual downstroke. In patients with severe aortic stenosis, the carotid upstroke is delayed.
• Circumferential function: circumferential contraction of the left ventricular wall that is mainly driven by the myocytes located in the mid portion of the left ventricular wall.
• Class of recommendation for the procedure (aortic valve replacement in the case of aortic stenosis (AS)): for class I the benefit of the procedure mainly outweighs the risk and the procedure should be carried out; for class IIa it is reasonable to carry out the procedure; for class IIb the procedure may be considered; and for class III the procedure is not recommended because it is not useful and may be harmful. anatomy and morphology, the haemodynamic severity of AS, the response of the left ventricle to the pressure overload caused by AS and the patient's symptomatic status 3, 4 . On the basis of these assessments, patients can be diagnosed with mild, moderate or severe AS, which can all occur in the presence or absence of symptoms (TABLE 1) . Although Doppler echocardiography is the primary modality to assess the stage of AS, cardiac catheterization, which can measure cardiac blood pressure and flow, may be used to confirm the haemodynamic severity of the stenosis in patients with inconclusive or discordant echocardiography results 157 . However, this invasive technique is associated with increased risk of bleeding and cerebral embolism 158 , and should therefore only be considered in patients in whom the reclassification of the stenosis severity by catheterization would change the therapeutic management of the patient (such as AVR versus conservative management). For example, individuals who might benefit from catheterization assessment include symptomatic patients for whom a diagnosis of moderate AS versus severe AS cannot be decided using echocardiography.
Patients at risk for AS. Individuals with aortic sclerosis and those with a bicuspid valve (irrespective of the presence or absence of sclerosis) are considered to be at risk of developing AS. The identification of a bicuspid valve is usually done by echocardiography but might require other imaging modalities such cardiac magnetic resonance (CMR) or CT if the valve is calcified.
Aortic valve sclerosis is defined echocardiographically by focal areas of valve calcification and thickening with normal leaflet mobility and normal valvular haemo dynamics (FIG. 7; TABLE 2) . A systolic outflow murmur may be auscultated on physical examination. Although aortic sclerosis is clinically asymptomatic, its presence is independently associated with a 40% increase in the risk of a coronary event and a 50% increase in Nature Reviews | Disease Primers the risk of cardiovascular death 159 . The mechanism of adverse outcomes with aortic sclerosis is not entirely clear but the presence of aortic valve mineralization might be a marker for atherosclerosis and/or for altered phospho-calcium metabolism 22, 160 . (FIG. 7; TABLES 1,2) are generally asymptomatic unless they have other comorbidities that contribute to the emergence of symptoms. Classic physical findings of AS are a harsh, crescendo-decrescendo systolic murmur, a single second heart sound and a delayed carotid upstroke
Mild or moderate AS. Patients with mild or moderate AS
. Using Doppler echocardiography, the haemodynamic severity of AS can be measured accurately and reliably on the basis of the peak aortic jet velocity, mean transvalvular pressure gradient (mean gradient) and aortic valve area (AVA). With the development of calcific AS, there is a progressive reduction in the AVA that causes an acceleration of the flow (that is, increase in peak aortic jet velocity) and a loss of pressure (that is, increase in mean gradient) across the valve (FIG. 6; TABLE 2 ). AS is suspected upon the visualization of a thickened aortic valve with a restricted opening, and confirmed by the presence of an increased peak aortic velocity or mean pressure gradient. Echocardiography is also useful to assess the effects of AS on the geometry and the function of cardiac chambers, particularly of the left ventricle (FIGS 5,6).
Severe AS. Patients with severe AS (typically, those who have a peak aortic jet velocity of ≥4 m per s, a mean gradient of ≥40 mm Hg and an AVA of ≤1 cm 2 ; TABLES 1,2) may or may not have symptoms, and require a closer clinical and Doppler echocardiographic follow-up than those with mild or moderate forms of the disaese 3 . Classic symptoms of severe AS include dyspnoea and other symptoms of heart failure, angina and syncope. Patients with severe AS who are apparently asymptomatic according to medical history and physical examination should undergo exercise testing to confirm their asymptomatic status. Indeed, about one-third of patients with severe AS who are a priori asymptomatic in fact have exercise-limiting symptoms detected at an exercise stress test, and these patients should be referred for AVR 161, 162 . In addition, a potential marker for risk in AS is a marked increase in mean gradient (absolute increase in gradient >18-20 mm Hg) during exercise stress echocardiography, which predicts higher risk of cardiac events in the short term, independent of symptoms 161, 162 .
Low-gradient AS. The majority of patients with severe AS have a high peak aortic jet velocity and gradient (mean gradient ≥40 mm Hg). However, a substantial proportion of patients may have a low peak aortic jet velocity and mean gradient despite the presence of a small AVA (<1.0 cm 2 ). The most frequent cause of 'low-gradient' AS is the presence of a low-flow state. There are two main subtypes of low-flow, low-gradient AS (TABLES 1,2): 'classical' low-flow (stroke volume index <35 ml per m 2 ), low-gradient (mean gradient <40 mm Hg) AS with reduced LVEF (<50%) 163 ; and 'paradoxical' low-flow (stroke volume index <35 ml per m 2 ), low-gradient (mean gradient <40 mm Hg) AS with preserved LVEF (≥50%) 164 .
In classical low-flow, low-gradient AS, the decrease in stroke volume, and thus in transvalvular flow rate (stroke volume divided by left ventricular ejection time), are predominantly related to left ventricular systolic dysfunction, whereas in paradoxical low-flow, low-gradient AS, the low-flow state is generally due to pronounced left ventricular concentric remodelling with impaired left ventricular diastolic filling and reduced left ventricular longitudinal systolic function 156 . Other conditions, such as mitral regurgitation, mitral stenosis or atrial fibrillation can also contribute to the reduced left ventricular outflow in both classical and paradoxical low-flow, low-gradient AS.
In the presence of low flow, it is therefore difficult -using resting Doppler echocardiography or catheterization -to differentiate truly severe stenosis from pseudo-severe stenosis; that is, a situation in which the stroke volume is not sufficient to completely open a valve that is only mildly or moderately stenotic. In such low-flow conditions, the gradient might underestimate the stenosis severity, whereas the AVA might overestimate the severity. Low-dose dobutamine stress echocardiography should be used for patients with classical (low LVEF) low-flow, low-gradient AS to confirm stenosis severity. Dobutamine is used to mimic the effect of exercise on the heart, thereby increasing cardiac blood flow. Patients with a mean gradient of ≥40 mm Hg (or a peak aortic jet velocity of ≥4 m per s) and an AVA of <1.0 cm 2 with dobutamine stress echocardiography are considered to have truly severe AS (TABLE 2) . In patients who show persistent discordant grading (small AVA with a low mean gradient) during dobutamine stress echocardiography, it is useful to calculate the projected AVA at normal flow rate; a projected AVA of <1.0 cm 2 suggests that the patient has truly severe stenosis 165, 166 . Patients who have no or minimal increase in stroke volume (increase of <20%) upon dobutamine administration have a high risk of operative mortality with surgical AVR 163, 167 . Low-dose dobutamine stress echocardiography or dobutamine stress cardiac catheterization may also be used in patients with paradoxical low-flow, low-gradient AS 168 . However, these approaches are often not feasible owing to the presence of restrictive left ventricular physiology or because their results are inconclusive owing to limited increases in flow in response to stress.
In patients with classical or paradoxical low-flow, low-gradient AS in whom dobutamine stress echocardiography is not feasible or inconclusive, multidetector CT (MDCT), which is a high-resolution form of CT, can be used to quantify aortic valve calcium load and thereby corroborate stenosis severity and indication of AVR (FIG. 7; TABLE 2 ). The region of the aortic valve is assessed in contiguous axial slices and the calcium score is measured by the Agatston-modified method, in which calcification is defined as 4 adjacent pixels with density >130 Hounsfield units on the MDCT images. Studies have shown that different cut-off values of aortic valve calcium score (AU) should be used in women (>1,200 AU) compared with men (>2,000 AU) to identify haemodynamically severe stenosis 169, 170 . Furthermore, these studies suggest that aortic valve calcium density (the ratio of calcium load to cross-sectional area of the aortic annulus) might be superior to absolute calcium load in predicting haemodynamic severity and clinical outcomes. These studies also showed that different cut-off values should be used in women (>300 AU per cm 2 ) compared with men (>500 AU per cm 2 ) 169, 170 . The aortic valve calcium load or density is also a powerful predictor of the risk of fast stenosis progression and of mortality [170] [171] [172] . Finally, a substantial proportion of patients with AS have a small AVA and low mean gradient but a normal flow (stroke volume index >35 ml per m 2 ). This category is often referred to as normal-flow, low-gradient AS and might be related to inherent discrepancies in the criteria used to define severe AS (in terms of AVA and mean gradient) 173 and/or to markedly reduced aortic compliance 169 . Patients with normal-flow, low-gradient AS generally have less advanced disease and better outcomes compared with patients who have high-gradient or low-flow, low-gradient AS 174 . However, if the patient is symptomatic, aortic valve calcium scoring using MDCT can be considered to confirm stenosis severity 169 .
Emerging biomarkers
Other imaging or blood biomarkers of the severity of AS, and its deleterious effects on the left ventricle and other cardiac chambers, may also be useful to predict risk of rapid disease progression and adverse events. These biomarkers may be particularly helpful in identifying patients with asymptomatic severe AS who may benefit from early 'prophylactic' AVR.
Biomarkers of aortic valve biology and flow pattern.
Positron emission tomography (PET) combined with MDCT (PET-MDCT) is a feasible and reproducible method that combines anatomical imaging from MDCT with molecular imaging from PET. The valvular uptake of 18 F-sodium fluoride ( 18 F-NaF) measured by PET-MDCT is a marker of an active mineralization process within the valve [175] [176] [177] (FIG. 8) .
18
F-NaF uptake correlates well with AS severity and it might provide incremental value beyond aortic valve calcium scoring to predict AS progression over time 172 . This method might also be useful in assessing the effect of new pharmacotherapies on AS progression. In addition, CMR might be useful to assess valve biology and flow. For instance, data from a previous study suggest that in the future CMR might be able to assess not only the amount of valvular calcification (as can be achieved with MDCT) but also the amount of fibrous-rich and lipid-rich valve tissue 178 . Moreover, CMR with four-dimensional flow modality might also one day be used to visualize flow patterns in the aorta and therefore to identify patients with AS who are at risk of developing aortic aneurysm and aortic dissection (a breach in the lining of the aorta that causes blood to flow between the layers of the wall of the aorta, forcing layers apart) 179, 180 (FIG. 9) .
Biomarkers of the effect of AS on the left ventricle.
Detection of subclinical left ventricular dysfunction using biomarkers might prove useful in identifying patients who may need early therapeutic intervention. For example, reduced longitudinal strain is useful to identify subclinical left ventricular dysfunction and to predict risk of cardiac events in patients with asymptomatic AS and preserved LVEF [181] [182] [183] [184] [185] [186] . However, further studies are needed to harmonize the different strain analysis platforms between vendors and to propose an optimal cut-off value of longitudinal strain that identifies patients at high risk of develop ing left ventricular dysfunction and symptoms in the short term.
Blood levels of B-type natriuretic peptide (BNP) might also be a useful marker of left ventricular function, as it is secreted from the left ventricle in response to mechanical stress. Although BNP can be used for risk stratification, there is an important inter-study variability in the cut-off serum values of BNP that have been used to identify highrisk patients. A 2014 study proposed the use of the BNP ratio (the measured value of BNP divided by the expected value of BNP, adjusted for the age and sex of the patient) to overcome this limitation. A BNP ratio of >1 was found to be a powerful independent predictor of mortality in AS, even in patients with asymptomatic AS 187 . Hence, the BNP ratio as well as its increase during follow-up might be helpful in enhancing risk stratification in AS.
Besides longitudinal strain and BNP, the extent of myocardial fibrosis represents a maladaptive response of the left ventricle to pressure overload from AS. Previous studies [188] [189] [190] [191] have reported that approximately 20-30% of patients undergoing AVR for severe AS have severe myocardial fibrosis documented by CMR or myocardial biopsies. Myocardial fibrosis is often not reversible (or only partially reversible) and is associated with increased risk of cardiovascular events and mortality during follow-up as well as persistence of left ventricular dysfunction and symptoms following AVR [188] [189] [190] 192, 193 . Therefore, the quantification of myocardial fibrosis by CMR (FIG. 10) could potentially be useful in recommending early AVR in patients with asymptomatic severe AS before extensive fibrosis and ensuing irreversible myocardial dysfunction have developed or to improve operative risk stratification and to assess potential utility versus futility of AVR in patients with low-flow, low-gradient AS. However, further studies are needed to improve the standardization of the different CMR methods for quantification of myocardial fibrosis and to establish the thresholds that should be used clinically to identify patients who are at risk for irreversible myocardial dysfunction. The largescale use of CMR in the AS population is also limited by its high cost and low availability.
Emerging blood biomarkers, such as high-sensitivity cardiac troponin 194, 195 , growth/differentiation factor 15 (GDF15), soluble IL-1 receptor-like 1 (IL-1RL1; also known as ST2) and miRNAs [196] [197] [198] , might be helpful to detect subclinical and/or irreversible myocardial dysfunction, but their incremental value beyond established clinical, echocardiographic, tomographic and blood biomarkers remains to be shown.
The main limitation of all aforementioned imaging and blood biomarkers of left ventricular function is that they are non-specific and may be altered by other concomitant diseases, such as hypertension, diabetes mellitus and coronary artery disease. Therefore, these biomarkers should always be interpreted in conjunction with the standard parameters of stenosis severity. Finally, further studies are needed to establish the incremental role of these emerging blood or imaging biomarkers to identify the patients who might benefit from earlier intervention.
Conclusions
In summary, the two main risk factors for calcific AS are older age and bicuspid aortic valve. Other risk factors include metabolic syndrome, diabetes, hypertension, smoking and increased plasma Lp(a). There is currently no preventive or pharmaco-therapeutic approach that has proved effective to prevent the onset or to slow the progression of calcific AS. The initial screening for this disease is generally based on the auscultation of a systolic murmur by the primary care physician or general cardiologist. Doppler echocardiography is the method of choice to diagnose AS and to assess its severity as well as to follow disease progression over time. Quantification of aortic valve calcium load by MDCT may be useful to corroborate stenosis severity in patients in whom echocardiography is neither feasible nor conclusive, which is often the case in the setting of low-flow, low-gradient AS. Measurement of circulating BNP levels, assessment of global longitudinal strain by speckle tracking and detection of myocardial fibrosis by CMR are emerging biomarkers that might improve the detection of subclinical left ventricular dysfunction and thus the determination of the optimal timing for AVR.
Management
The only treatment available to patients with symptomatic severe AS is to implant a prosthetic heart valve either surgically or percutaneously (through a catheter). The therapeutic management is similar for calcific and rheumatic AS. As discussed above, there is no pharmacotherapy that specifically targets AS to prevent progressive leaflet calcification or to delay the time to valve replacement 3, 199 . Although there was hope that statins would fill that void, several randomized trials showed no effect of statins on haemodynamic progression or AS-related clinical events [152] [153] [154] . However, the combination of simvastatin (a drug that lowers plasma LDL cholesterol levels) and ezetimibe (a drug that decreases cholesterol absorption in the small intestine) did reduce ischaemic cardiovascular events in patients with mild to moderate AS 153 . Therefore, as valve stenosis progresses into the moderate to severe range, greater vigilance is required in terms of assessment for symptoms associated with significant AS, to decide when to carry out AVR.
Management decisions regarding AVR are often straightforward (FIG. 11) . However, in the current era of transcatheter AVR (TAVR), there are more options to consider when intervention is contemplated than in previous decades (FIGS 12, 13) . In addition, older (>80 years of age) and sicker patients who were not previously candidates for definitive therapy are being treated 200, 201 . Increasingly, clinicians must integrate complex information about the severity of AS, ambiguous symptoms, left ventricular remodelling and function, comorbidities, frailty and disabilities to make decisions on whether, when and how to carry out AVR 3, 199, 202 . This complex information ought to be discussed and debated by a heart valve team -a multidisciplinary group of cardiac surgeons, interventionalists, cardiac imaging experts, and often nurses, geriatricians and anesthesiologists [203] [204] [205] . In addition, it is important for management decisions to centre on patients and not to be myopically focused on AS severity alone 3 . First, it should be decided whether valve replacement is indicated. Next, consideration can be given to how the valve should be replaced (surgical versus transcatheter) (FIGS 12,13; TABLE 3) . Finally, at any stage of AS, associated medical conditions such as atrial fibrillation, coronary disease, hypertension and heart failure should be treated according to guideline recommendations 3, 4, 199 .
Indications for aortic valve replacement
Symptomatic severe AS. Severe high-gradient AS accompanied by symptoms related to AS is the most common and straightforward indication for AVR, and those with severe AS who present with symptoms and/ or left ventricular systolic dysfunction (defined as a LVEF of <50%) have a firm (class I; BOX 1) indication for AVR 3, 4 (FIG. 11; TABLE 1 ). Low-flow, low-gradient AS presents somewhat of a challenge, as the combination of a small AVA with a low gradient raises uncertainty about the severity of the stenosis and thus the indication of AVR. Symptomatic patients with classical low-flow, low-gradient and reduced LVEF (<50%) are reasonable candidates for AVR (class IIa indication; BOX 1) provided that there is anatomic evidence (MDCT calcium score) or haemodynamic evidence (peak aortic jet velocity of ≥4 m per s or mean gradient of ≥40 mm Hg with dobutamine stress echocardiography) that the AS is truly severe 3, 4, 170 . AVR may be considered in patients with classical low-flow, low-gradient AS who have no flow reserve with dobutamine stress echocardiography, but the operative risk is higher 4, 163, 167, 206 . It is also reasonable to carry out AVR in symptomatic patients with paradoxical low-flow, low-gradient and preserved LVEF (≥50%; class IIa indication) provided there is clinical, haemodynamic and anatomical evidence that the obstruction is severe and is the most likely cause of symptoms 3, 4, 168 . Although there has been some debate about the outcome and the therapeutic management of patients with paradoxical low-flow, low-gradient AS, a recent meta-analysis confirms that these patients have worse outcomes than those with moderate or highgradient severe AS, and that their survival is markedly improved by AVR 174 .
Asymptomatic severe AS.
Patients with severe AS who are asymptomatic by history but who have a reduced LVEF (<50%; TABLE 1), or who are undergoing another cardiac surgical procedure, should have their valve replaced (class I indication) 3, 4 (FIG. 11) . It is also reasonable to carry out AVR (class IIa indication) in asymptomatic patients with severe AS and decreased exercise tolerance, or who show a drop in blood pressure with exercise, and in those at low surgical risk with very severe AS (peak aortic jet velocity >5 m per s or 5.5 m per s, depending on the guidelines), or in those who have findings suggestive of rapid progression (severe valve calcification or increase in peak aortic jet velocity of ≥0.3 m per s per year) 3, 4 . Over the past half century, tremendous advances in operative management, techniques and valve design have transformed the outlook for patients with AS. Despite increasing age and comorbidities, the mortality associated with AVR has decreased dramatically during the past two decades 208, 209 . For an isolated AVR, the overall 30-day mortality rate is currently <3% as reported in the Society of Thoracic Surgeons (STS) database and German Aortic Valve Registry (GARY) 209, 210 . TABLE 3 presents the advantages and limitations of the different types of AVR. There has been a shift away from mechanical valves towards greater use of bioprosthetic valves, particularly in patients >65 years of age 209 (FIG. 12) . Increasingly, younger patients or those with an active lifestyle opt for a bioprosthetic valve to avoid anticoagulation, despite its shorter durability compared with a mechanical valve. The most frequently used bioprosthetic valves are the stented bioprostheses, which are composed of three biological leaflets made from porcine aortic valve or bovine pericardium and mounted on a metal or polymeric stented ring. Bioprosthetic valves also include stentless bioprostheses that are manufactured from intact porcine aortic valves or from bovine pericardium. These valves have better haemodynamics compared with stented valves but their implantation is more complex and thus requires longer cardiopulmonary bypass time. Sutureless stent-mounted bioprosthetic valves have also been developed to allow easier and faster implantation of the valve without sutures. Additional alternatives for AVR in younger patients include the implantation of an aortic homograft (aortic valve collected from a donor) or the Ross procedure, which involves the replacement of the diseased aortic valve with the patient's pulmonary valve followed by pulmonary valve replacement using a donor pulmonary valve [211] [212] [213] . However, these options are more controversial and less frequently used. A recent propensity analysis showed no difference in mortality or stroke among patients 50-69 years of age treated with a bioprosthetic valve versus a mechanical valve, although a bioprosthetic valve was associated with a higher incidence of reoperation and a mechanical valve was associated with a higher incidence of major bleeding during the 15-year follow-up 214 . A mini sternotomy, which is a minimally invasive way of carry ing out cardiac surgery, is a viable option for isolated AVR and is associated with similar mortality, but decreased morbidity and resource use, compared with a full sternotomy 215 .
Operative mortality for AVR varies according to the skill and the experience of the surgical team as well as hospital volume 216 . Increasing age and comorbidities substantially increase both operative and long-term mortality after AVR 217, 218 . Several risk scores, including the EuroSCORE (http://www.euroscore.org) and the STS risk calculator (http://riskcalc.sts.org), incorporate these factors to estimate operative risk. These risk scores are imperfect and being refined iteratively. They often do not include important factors such as frailty, chest wall radiation, porcelain aorta, pulmonary hypertension and liver cirrhosis. Owing to age, left ventricular dysfunction, multiple comorbidities and other factors, approximately one-third of patients with indications for AVR are not treated 200, 219 .
Transcatheter aortic valve replacement TAVR is a minimally invasive procedure that involves insertion of a bioprosthetic aortic valve within the orifice of the native stenotic valve using a catheter (FIG. 13) . For patients at high or prohibitive risk of operative mortality with surgical AVR, TAVR has been a transformative innovation, providing a life-saving treatment for patients who were previously not candidates for AVR 201, [220] [221] [222] [223] [224] (TABLE 3) . In the PARTNER Trial, there was a 20% absolute reduction in 1-year mortality (hazard ratio, 0.55; 95% confidence interval, 0.40 to 0.74) with TAVR compared with standard therapy (30.7% versus 50.7%, respectively) 201 . This survival benefit was accompanied by relief of symptoms and improvement in functional capacity in many patients 201, 225 . Randomized trials of balloon-expandable and self-expanding valves have also showed that TAVR is a viable alternative to surgery in patients at high risk for AVR 220, 221 (TABLE 4) .
TAVR may be carried out by several different approaches: the most common access routes include transfemoral, transapical and transaortic routes (FIG. 13; TABLE 5 ). Approximately two-thirds (56-75%) of TAVR procedures are carried out via a transfemoral approach [226] [227] [228] [229] . As catheter sheath sizes decrease, the balance is anticipated to shift even further towards a transfemoral approach. A transfemoral approach is Nature Reviews | Disease Primers
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LGE associated with lower mortality and quicker recovery than alternative access approaches [227] [228] [229] . Other approaches include access via the subclavian, axillary or carotid arteries. There have also been recent reports of transcaval approaches 230 . Balloon-expandable and self-expanding transcatheter valves have so far been the most rigorously studied valve types, specifically the CoreValve (Medtronic, Dublin, Ireland) and SAPIEN (Edwards, Irvine California, USA) valves 201, 220, 221, 224, 226, 231, 232 (FIG. 13; TABLE 5). This clinical arena is a very active area of development that includes iterative improvements on existing valves and novel designs 233 . Although TAVR has been a successful therapy in many ways, several complications and challenges have been encountered 233 . The most notable has been paravalvular aortic regurgitation [234] [235] [236] . The association between moderate or severe paravalvular aortic regurgitation and increased mortality has been clearly established, with some studies even suggesting that this adverse association extends to mild regurgitation 235, 237, 238 . Other complications of TAVR have included major vascular injury, heart block requiring a permanent pacemaker and acute kidney injury; more rare complications include stroke, aortic rupture and coronary obstruction 233 .
The TAVR field is evolving rapidly. Clinical trials comparing TAVR with surgery in intermediate risk populations are ongoing with results expected soon (TABLE 4) . Surgical AVR has excellent results with low mortality in low risk populations 209 . For TAVR to make inroads into lower risk populations, device improvements are needed (principally to reduce paravalvular regurgitation and heart block, which is an arrhythmia that occurs when electrical impulses in the heart are blocked or delayed), vascular and stroke complications must be minimized and valve durability needs to be shown. There is a growing movement away from general anaesthesia to conscious sedation that might decrease the morbidity associated with the procedure 239 . Finally, valve-in-valve procedures for failed bioprostheses are becoming more common as an alternative to re-doing surgical AVR 240 .
Surgical or transcatheter aortic valve replacement
The choice of how to carry out AVR should occur only after a decision that AVR is indicated
Surgical AVR is currently indicated for patients with low to moderate surgical risk and TAVR is indicated for patients at prohibitive risk for surgery 3, 4 (FIG. 11; TABLE 3 ).
Patients may be at prohibitive risk for surgery owing to 3, 4 . Factors of importance to this decision include anatomical considerations, concomitant coronary disease and associated mitral or tricuspid valve disease. In patients with considerable associated mitral or tricuspid regurgitation, it is unclear whether concomitant surgical repair of the mitral or tricuspid valve at the time of AVR would improve clinical outcomes 242, 243 . Although TAVR is generally associated with a survival advantage compared with conservative (no AVR) management, there is a sizeable subgroup that dies soon after TAVR or does not experience an improvement in quality of life, suggesting potential futility of TAVR in some patients 201, 202, 220, 244, 245 . For instance, among inoperable patients treated with TAVR in the PARTNER I Cohort B trial (TABLE 4) , at 1 year after the procedure, approximately 31% had died and 18% had less than a moderate improvement in their quality of life or New York Heart Association functional class 201, 244 . Among patients treated in the high-risk Cohort A of the PARTNER I trial with TAVR or surgical AVR (TABLE 4) , death from non-cardiovascular causes was more common than death from cardiovascular causes 48 . Moreover, when cause of death was difficult to categorize, it often occurred in frail patients who were failing to thrive 246 . Therefore, when lifespan or quality of life is markedly limited by frailty, non-cardiac disease, or mental or physical disability, the potential benefit of AVR may be low 11 . These cases highlight the importance of a heart valve team in the management decisions of these complex patients 3, 4 . In some of these patients, the most appropriate approach is palliative care, taking the values and preferences of the patient and family into consideration in the decision-making process 202 .
Management of coronary disease in patients with AS
The prevalence of coronary disease in the setting of severe AS increases with age and was as high as 75% in recent trials involving mostly very elderly patients 201, 220 . Decisions regarding revascularization at the time of valve replacement used to be somewhat simpler when surgical valve replacement was the only option. If considerable coronary artery stenosis was present at preoperative coronary angiogram, coronary artery bypass graft was carried out at the time of valve replacement surgery. With the emergence of TAVR, decisions regarding the treatment of coronary disease have become more complex, including which coronary lesions to treat versus which to leave alone, how to treat them (percutaneous versus bypass) and when to treat them (before, during or after valve replacement) 247 . These decisions are influenced by numerous factors including lesion location and complexity, overall burden of coronary disease, the presence or absence of angina, left ventricular function, bleeding risk on dual antiplatelet therapy and other factors. How these decisions affect clinical outcomes requires further investigation, as many questions remain 247, 248 . The way in which coronary disease should influence decisions between valve replacement with TAVR and surgical valve replacement is also unclear in some scenarios. A detailed discussion of these complex decisions is beyond the scope of this Primer, but has been recently reviewed elsewhere 247, 249 .
Balloon aortic valvuloplasty
Balloon aortic valvuloplasty (BAV), which uses the pressure of an inflated balloon to widen the opening of the stenotic valve, is not a definitive therapy for AS 3 
.
The changes produced by BAV in the valve area and transvalvular pressure gradient are usually modest and short-lived (weeks to months) 250, 251 . In particularly ill patients, BAV may be used as a 'bridge' to stabilize the patient prior to definitive therapy with valve replacement 3 . When there is uncertainty as to whether a patient will benefit clinically from valve replacement owing to b Nature Reviews | Disease Primers a markedly depressed left ventricular function or concomitant oxygen-dependent lung disease, or other factors, a BAV may have diagnostic use to determine whether valve replacement is appropriate 202 . In patients with severe AS who are undergoing non-cardiac surgery, a BAV is generally not warranted unless the patient is symptomatic or haemodynamically unstable and needs to undergo non-cardiac surgery before aortic valve replacement can be carried out 3 . In some circumstances, a BAV may be used for palliative care as there is some evidence that it might provide a short-term benefit in terms of improved survival, functional capacity and quality of life, but these benefits are not sustained 251 .
Quality of life
Severe AS primarily impairs quality of life by causing heart failure symptoms, including shortness of breath, fatigue and diminished functional capacity 199, 252 . However, because patients who develop severe AS are usually older adults, these symptoms may also partly result from normal ageing, numerous comorbidities or frailty 202 . In older patients at high or extreme surgical risk undergoing TAVR, disease-specific and generic health status are often extremely poor 221, 224, 244, 245 . Given the high prevalence of frailty and disability in this patient population, the relationship between valvular stenosis and overall quality of life is also complex and variable 202 . AVR is indicated in patients with severe symptomatic AS both to increase life expectancy and improve symptoms and quality of life 3, 4, 199, 202, 252, 253 . For a patient with severe AS and heart failure symptoms, who is at low surgical risk, surgical AVR is associated with a fairly predictable improvement in shortness of breath and functional capacity. For patients who are at high risk for surgical interventions, who were previously not treated with AVR, TAVR has been a transformative innovation that has improved survival and quality of life 200, 201 . Compared with inoperable patients treated with conservative management, patients treated with TAVR had less severe heart failure symptoms and better disease-specific and generic health status over the year after randomization 201, 244 . To determine the anticipated benefit of valve replacement in terms of quality of life, it is important to consider how much of the patient's symptoms and impaired health status are due to the valvular obstruction and heart failure versus other comorbidities and geriatric conditions 253 . This can be challenging to determine. When a patient's diminished quality of life is clearly related to heart failure symptoms from severe AS, valve replacement conveys a predictable and noticeable improvement in quality of life and extends life expectancy. However, some patients have residual heart failure symptoms (albeit not as severe) after valve replacement owing to persistent diastolic dysfunction; this may manifest in a similar manner to the common syndrome of heart failure with preserved LVEF. When poor health status is principally due to comorbidities and geriatric conditions, valve replacement might lead to an unsatisfactory result both in terms of decreased survival and a decline or lack of improvement in quality of life [253] [254] [255] [256] . Elucidating which factors contribute to worse quality of life after TAVR and identifying how those factors might be targeted with adjunctive interventions to improve outcomes require further study. It is likely that systemic, non-cardiac factors have an important role.
Outlook
Valve biology
Although long considered to be a passive and degenerative process, it is now clear that calcific AS results from an active biology that promotes fibrosis and calcification of the valve leaflets 1 . The pathobiology of AS is complex and probably involves genetic factors, multiple signalling pathways, ageing, sex hormones, haemodynamic factors and shear stress, and the systemic milieu. Disease initiation and progression are influenced by different factors. Several laboratories worldwide are working to elucidate the pathobiology of aortic sclerosis and stenosis, which will probably yield novel insights into potential therapeutic targets to prevent or to reverse calcific aortic valve disease.
Pilot trials to slow disease progression
Several intervention studies have been carried out to test the hypothesis that lipid lowering with statin medications would slow the progression of AS; however, the results were generally disappointing [152] [153] [154] . With new insights into valve biology, there will probably be a new wave of clinical trials testing interventions that target diverse pathways to slow the progression of (or even reverse) calcific AS. Specific interventions might target the initiation of disease or the progression of disease.
Promising targets on the horizon include Lp(a), the renin-angiotensin system, RANKL and ectonucleotidases. Novel composite end points are likely to be developed for these trials based on the mechanism of action of the intervention and the phase of disease targeted.
AS as a disease of the left ventricle
The left ventricular response to chronic pressure overload from AS is characterized by hypertrophic remodelling (myocyte hypertrophy and fibrosis) and diastolic and systolic dysfunction. In many ways, this left ventricular response considerably influences the morbidity and the mortality of the disease 199, [257] [258] [259] [260] . Future research will probably clarify the mechanisms driving the formation of fibrosis in the pressure-overloaded heart and will elucidate the abnormal diastolic properties (such as stiffness versus relaxation) involved in AS. In asymptomatic patients, targeting the adverse remodelling sequelae of the valvular stenosis with a therapeutic medical intervention may delay the onset of symptoms and may enable the delivery of new valves into healthier hearts, thereby potentially improving long-term cardiac performance and functional capacity.
TAVR will be used in lower risk populations
With iterative improvements in transcatheter valves and lower procedural complications (less paravalvular leak, permanent pacemakers, stroke and vascular injury), TAVR will probably start to be used in lower risk populations (TABLE 4) . However, questions about valve durability will need to be addressed. Although TAVR might become a viable option in patients with low risk and isolated AS, there will probably continue to be a group of patients for whom surgical AVR is preferable because it allows for more optimal treatment of concomitant pathology such as left main coronary disease or severe mitral or tricuspid valve disease. The currently available option of a transcatheter valve-in-valve procedure might lead cardiac surgeons to implant bioprosthetic valves (rather than mechanical valves) in younger patients, with the understanding that a new bioprosthetic valve can be subsequently implanted using TAVR. 
Improved accuracy of risk prediction for TAVR
Although the STS score and EuroSCORE are reasonably accurate in predicting morbidity and mortality after TAVR, they were developed in patient cohorts of younger individuals with fewer comorbidities undergoing cardiac surgery 261 . With multiple clinical trials and registries collecting detailed data on patients undergoing TAVR, there will be several risk prediction models developed specifically in and for TAVR patients that will improve upon existing ones. These scores will incorporate factors associated with older age (for example, frailty, disability and cognitive impairment) and will be developed to predict quality of life outcomes, not just mortality.
Increased use of biomarkers
Biomarkers have not been widely used in the management of patients with AS. Natriuretic peptides, such as BNP, are somewhat of an exception, but their role in management decisions has not been clearly defined 3, 4 . In the coming years, there will be more specific cut-offs of natriuretic peptide levels to guide management decisions 187 . High sensitivity cardiac troponin will be more routinely integrated into our evaluation of patients with AS 194 . Increasingly, as in non-AS heart failure populations, a multimarker approach will be taken to measure diverse biological pathways in a more integrated manner to gain insight into ventricular health and systemic factors that might affect clinical outcomes and influence management strategies regarding valve replacement and adjunctive therapies 198 .
Tailored management strategies for AVR Treatment decisions will become more personalized regarding when, whether and how to carry out valve replacement. Previously, management decisions were mainly conceptualized in terms of the severity of AS and the presence or absence of symptoms. Phenotyping and risk stratification has and will become more sophisticated, allowing for more nuanced management decisions. The left ventricular response to a given degree of pressure overload, systemic factors, biomarkers, patient symptoms and operative risk will be integrated alongside an assessment of AS severity to influence management strategies regarding valve replacement.
In the near future, the realization of randomized trials might pave the way for new indications for AVR. The trials that should be considered a priority by the cardiology community include early 'prophylactic' AVR versus a watchful waiting strategy in asymptomatic patients with severe AS, and TAVR combined with heart failure therapy versus heart failure therapy alone in patients with moderate AS, low LVEF and heart failure symptoms (TABLE 4) . Also, the data from ongoing and future trials will help to better individualize the type of AVR according to the baseline risk profile of patients. Results from some recent studies suggest that TAVR might be preferable to surgical AVR in patients with diabetes, chronic obstructive pulmonary disease, pulmonary hypertension, small aortic annulus and low-flow, low-gradient AS [262] [263] [264] [265] [266] .
Interventions after AVR to improve clinical outcomes
Given that AS is conceptualized as a mechanical problem (valve obstruction) in need of a mechanical solution (valve replacement), it is common to view the problem or disease of AS as 'fixed or solved' after the valve is replaced, with little attention directed towards strategies and interventions that might improve clinical outcomes in the post-valve replacement period. We anticipate that there will be a growing recognition of factors that impair an optimal clinical outcome in patients with AS after valve replacement, and that interventions will be identified that might improve these outcomes. These might include interventions such as adjunctive medical therapies (for example, anti-fibrotic and anti-hypertrophic agents) to improve left ventricular reverse remodelling and function, or lifestyle interventions to improve outcomes for frail patients undergoing TAVR. 
